IQVIA (IQV)

Company ID: 255 | CIK: 0001478242
10-Q view:
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

Business Unit / Product Segments

No 10-Q data
No 10-Q data

Major Customers (% of Revenue)

No 10-Q data

Operational KPIs

Backlog (backlog)

Net New Business (bookings)

Contract medical sales reps (contractors)

No 10-Q data

Clients (customers)

No 10-Q data

Employee engagement (engagement)

No 10-Q data

Integrated Engagement Employees (headcount)

Clinical site accessibility (other)

No 10-K data

Clinical sites inaccessible (other)

No 10-K data

Common Stock Outstanding (other)

No 10-Q data

Common shares outstanding (other)

No 10-K data

Common stock outstanding (other)

No 10-Q data

Countries of Operation (other)

No 10-Q data

Countries of operation (other)

Data Feeds (other)

No 10-Q data

Data Suppliers (other)

No 10-Q data

Data feeds (other)

No 10-Q data

Data suppliers (other)

No 10-Q data

Days sales outstanding (other)

No 10-K data

Delivery hub locations (other)

No 10-K data

EHR patient lives covered (other)

No 10-Q data

Employee Resource Group membership (other)

No 10-Q data

Employee engagement (other)

No 10-Q data

Female managers (other)

No 10-Q data

Female workforce (other)

No 10-Q data

Foreign currency revenue share (other)

No 10-K data

Healthcare professionals tracked (other)

No 10-Q data

Healthcare records received (other)

No 10-Q data

Healthcare records received annually (other)

No 10-Q data

Healthcare transactions processed (other)

No 10-Q data

Longitudinal patient records (other)

No 10-Q data

Markets tracked (other)

No 10-Q data

Markets with Product Level Tracking (other)

No 10-Q data

Non-USD denominated revenue share (other)

No 10-K data

Non-USD revenue share (other)

No 10-K data

Non-USD service revenues (other)

No 10-K data

Number Of Reportable Segments (other)

Number of Reportable Segments (other)

Patient Records (other)

No 10-Q data

Patient records (other)

No 10-Q data

Patient recruitment rate (other)

No 10-K data

Pharmaceutical coverage (other)

No 10-Q data

Pharmaceutical market coverage (other)

No 10-Q data

Positions eliminated (other)

No 10-K data

Proprietary Data (other)

No 10-Q data

Proprietary Data Volume (other)

No 10-Q data

Proprietary data volume (other)

No 10-Q data

Real world data assets (other)

No 10-Q data

Shares outstanding (other)

No 10-Q data

US revenue share (other)

No 10-Q data

Unique Non-Identified Patient Records (other)

No 10-Q data

Offices and laboratories (properties)

No 10-Q data

Remaining performance obligations (rpo)

Registered digital service users (users)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data
No 10-Q data

Demographics

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No 10-Q data

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-30restructuringin_progress2027-12-31GlobalCompany-wideUSD 63 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2026 actions to align resources, reduce overcapacity, and integrate acquisitions; expected to continue throughout 2026 and into 2027. Q2 2026 severance and related costs of $63 million; YTD expense of $114 million with $77 million paid in H1. Accrual balance of $67 million at June 30, 2026, majority expected to be paid in 2026 and 2027. No employee counts disclosed.
2026-06-30restructuringin_progressGlobalCompany-wide; restructuring costs are not allocated to reportable segmentsUSD 114 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and related costs expense of $114M for the six months ended June 30, 2026 ($63M in Q2 2026), net of reversals; accrual balance of $67M at June 30, 2026 after $77M of payments. Actions involve consolidating functions, eliminating redundant positions, and integrating acquisitions, and are expected to continue through 2026 and into 2027. No employee count, announcement date, or completion date disclosed. Reversals reflected staff redeployment and higher-than-expected voluntary terminations.
2026-06-30restructuringin_progress2027-12-31GlobalAll segmentsUSD 114 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions to align resources and reduce overcapacity; expected to continue throughout 2026 and into 2027. Includes consolidating functional activities and eliminating redundant positions.
2026-06-30restructuringin_progressUSD 63,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progress2027-12-31GlobalUSD 51 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to consolidate functions, eliminate redundant positions and align resources with customer requirements; expected to continue throughout 2026 and into 2027. Severance accrual of $43 million at quarter-end; majority expected to be paid in 2026 and 2027. No employee count disclosed.
2026-03-31restructuringin_progressGlobalUnallocated — across the enterpriseUSD 51 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program to consolidate functions, eliminate redundant positions and reduce overcapacity amid changing market conditions and acquisition integration; actions expected to continue through 2026 and into 2027. Q1 2026 expense of $51M net of reversals (reversals driven by staff redeployment and higher-than-expected voluntary terminations); severance accrual roll-forward: $31M opening, $38M payments, $43M closing balance. No employee count affected is disclosed. Restructuring costs are not allocated to reportable segments.
2026-03-31acquisition_additioncompletedNot disclosedNot disclosedbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Individually and in aggregate immaterial acquisitions completed in Q1 2026; net assets acquired of $53M including $30M goodwill attributed partly to assembled workforce. No headcount added is quantified; purchase price allocation is preliminary.
2026-03-31restructuringin_progress2027-12-31GlobalAll segmentsUSD 51 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions include consolidating functional activities, eliminating redundant positions, and aligning resources. Expected to continue throughout 2026 and into 2027. Employee count not disclosed.
2026-03-31restructuringin_progressUSD 51,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-12-31restructuringin_progress2026-12-31GlobalGlobal operations (all segments)USD 105 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2025 expense of $105M, net of reversals, primarily severance and exit costs; $97M paid during 2025, $31M accrual at year-end. Actions include consolidating functions, eliminating redundant positions; filer states actions expected to occur throughout 2026. No employees-affected count disclosed.
2025-12-31restructuringannounced2026-01-01GlobalCorporate / reportable segment structureother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Effective January 1, 2026 the Company restructured operations to reduce reportable segments from three to two (Contract Sales & Medical Solutions folded into renamed Commercial Solutions; Real-World Late Phase moved to R&DS). Recast segment information begins with the Q1 2026 Form 10-Q; no headcount or charge quantified.
2025-12-31acquisition_additioncompletedGlobalAll three reportable segmentsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Several individually immaterial acquisitions completed in 2025; $1,714M net of cash invested and $1,279M goodwill recorded. Headcount added through acquisitions not disclosed.
2025-12-31restructuringin_progress2025-01-012026-12-31GlobalAll segmentsUSD 105 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Ongoing efforts to streamline global operations, reduce overcapacity, and integrate acquisitions. Actions expected to continue throughout 2026.
2025-12-31restructuringin_progressUSD 105,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-30restructuringin_progress2026-12-31USD 81 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2025 actions to align resources, reduce overcapacity, and integrate acquisitions; expense net of reversals of $81 million for nine months ended September 30, 2025; severance accrual balance of $33 million at quarter-end; actions expected to continue through 2025 and into 2026; employee counts not disclosed
2025-09-30restructuringin_progressGlobalConsolidated (not allocated to reportable segments)USD 81 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program to consolidate functions, eliminate redundant positions and reduce overcapacity; no employee count disclosed. Severance accrual: $21M at 2024-12-31, $81M expense net of reversals, $(71)M payments, $33M at 2025-09-30. Reversals attributed to staff redeployment and higher-than-expected voluntary terminations. Actions expected to continue through 2025 and into 2026; majority of accruals to be paid in 2025 and 2026. Q3-only restructuring expense was $20M.
2025-09-30acquisition_additioncompletedNot disclosedTechnology & Analytics Solutions; Research & Development Solutions; Contract Sales & Medical Solutions (goodwill by segment)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Individually and in aggregate immaterial acquisitions completed during the nine months ended 2025-09-30; net assets acquired $1,073M including $596M goodwill and $378M intangibles, plus $127M fair value of noncontrolling interests. No headcount added disclosed; includes an $8M step acquisition gaining control of a former unconsolidated affiliate.
2025-09-30restructuringin_progress2026-12-31GlobalAll segmentsUSD 81 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing actions to align resources and reduce overcapacity. Expected to continue throughout 2025 and into 2026. Employee count not disclosed.
2025-09-30restructuringin_progressUSD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progress2026-12-31USD 61 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2025 actions to align resources and reduce overcapacity, including consolidating functions and eliminating redundant positions; expected to continue through 2025 and into 2026. Severance expense of $61 million (net of reversals) recorded in the six months ended June 30, 2025; severance accrual balance of $34 million at quarter-end, with majority expected to be paid in 2025 and 2026. No employee counts disclosed.
2025-06-30restructuringin_progress2026-12-31GlobalUnallocated — restructuring costs are not allocated to reportable segmentsUSD 61 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2025-06-30 severance and related costs expense of $61M net of reversals (Q2: $32M); accrual $21M at 2024-12-31 to $34M at 2025-06-30. Actions involve consolidating functions, eliminating redundant positions; expected to continue through 2025 and into 2026. No employee count disclosed.
2025-06-30acquisition_additioncompletedPrimarily Technology & Analytics Solutions and Research & Development Solutions (per goodwill roll-forward)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Individually and in aggregate immaterial acquisitions in 1H 2025 plus a step acquisition consolidating a former unconsolidated affiliate; net assets acquired $421M including $236M goodwill. Headcount added not disclosed.
2025-06-30restructuringin_progress2026-12-31GlobalAll segmentsUSD 61 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing actions to align resources and reduce overcapacity; expected to continue throughout 2025 and into 2026. Employee count not disclosed.
2025-06-30restructuringin_progressUSD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progress2026-12-31GlobalUSD 29 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2025 actions to align resources and reduce overcapacity, including consolidating functions and eliminating redundant positions; expected to continue through 2025 and into 2026. Q1 2025 severance expense of $29 million (net of reversals); severance accrual of $28 million at quarter-end, mostly to be paid in 2025-2026. No employee counts disclosed.
2025-03-31restructuringin_progressGlobalNot specified; restructuring costs are not allocated to reportable segmentsUSD 29 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2025 severance expense, net of reversals, was $29M; accrual rolled from $21M at 2024-12-31 to $28M at 2025-03-31 after $23M of payments. No employee count disclosed. Actions involve consolidating functions, eliminating redundant positions, and aligning resources; expected to continue through 2025 and into 2026, with most accruals paid in 2025 and 2026. Reversals reflected redeployment of staff and higher-than-expected voluntary terminations.
2025-03-31restructuringin_progress2026-12-31GlobalGlobalUSD 29 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing actions to align resources and reduce overcapacity; expected to continue throughout 2025 and into 2026. Employee count not disclosed.
2025-03-31restructuringin_progressUSD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-31restructuringin_progressGlobalCompany-wide (consolidating functional activities, eliminating redundant positions, aligning resources with customer requirements)USD 67 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2024 restructuring expense of $67 million net of reversals, primarily severance and other exit-related costs, from plans to align resources and reduce overcapacity; actions expected to continue into 2025. Severance accrual balance of $21 million at 2024-12-31, majority expected to be paid in 2025. No employee count disclosed. Same program also discussed in MD&A; extracted once from the footnote.
2024-12-31restructuringin_progress2025GlobalConsolidating functional activities, eliminating redundant positions, aligning resources with customer requirementsUSD 67 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2024 restructuring expense of $67 million, net of reversals, primarily severance and exit-related costs; actions described as ongoing efforts to streamline global operations, reduce overcapacity and integrate acquisitions, expected to continue into 2025. Severance accrual balance was $21 million at 2024-12-31, with the majority expected to be paid in 2025. No employee count disclosed. Reversals reflected redeployment of staff and higher-than-expected voluntary terminations.
2024-12-31acquisition_additioncompletedGlobalTechnology & Analytics Solutions and Research & Development Solutionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Several individually immaterial acquisitions completed during 2024 (net assets acquired $847 million, including $532 million goodwill); no acquired headcount disclosed. Goodwill attributed primarily to assembled workforce, expected synergies and new client relationships.
2024-12-31restructuringin_progress2025-12-31GlobalVariousUSD 67 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Ongoing efforts to streamline global operations and reduce overcapacity. Actions expected to continue throughout 2025.
2024-12-31restructuringin_progressUSD 67,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-30restructuringin_progress2025-12-31USD 71 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2024 restructuring actions to align resources, reduce overcapacity, and integrate acquisitions; include consolidating functional activities and eliminating redundant positions. YTD severance and related costs of $71 million (net of reversals); severance accrual balance of $46 million at September 30, 2024, with majority expected to be paid in 2024 and 2025. No employee counts disclosed. Costs not allocated to segments.
2024-09-30restructuringin_progressGlobalNot specified; actions include consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirementsUSD 71 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and related costs expense, net of reversals, for the nine months ended 2024-09-30; accrual balance $46M at period end ($36M at 2023-12-31, $62M paid during period). No employee count disclosed. Actions expected to continue throughout 2024 and into 2025; majority of accruals to be paid in 2024 and 2025. Reversals reflected changes in estimates from staff redeployment and higher-than-expected voluntary terminations.
2024-09-30acquisition_additioncompletedNot specifiedTechnology & Analytics Solutions and Research & Development Solutions (goodwill of $289M and $181M, respectively)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several individually immaterial acquisitions completed during the nine months ended 2024-09-30; net assets acquired of $734M including $470M goodwill. Headcount added through these acquisitions is not disclosed; purchase price allocation is preliminary.
2024-09-30restructuringin_progress2025-12-31GlobalAll segmentsUSD 71 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing actions to align resources and reduce overcapacity. Expected to continue throughout 2024 and into 2025. Majority of accruals expected to be paid in 2024 and 2025.
2024-09-30restructuringin_progressUSD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progress2025-12-31USD 43 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2024 actions to align resources, reduce overcapacity, and integrate acquisitions; severance expense net of reversals of $43 million in the six months ended June 30, 2024; accrual balance of $42 million at quarter-end; actions expected to continue through 2024 and into 2025. No employee counts disclosed.
2024-06-30restructuringin_progressGlobalNot allocated to reportable segments; global operationsUSD 43 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six-months expense net of reversals; actions include consolidating functions, eliminating redundant positions, and integrating acquisitions; expected to continue throughout 2024 and into 2025; no employee count disclosed; severance accrual was $42M at 2024-06-30
2024-06-30acquisition_additioncompletedPrimarily Technology & Analytics Solutions (goodwill allocation)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several individually immaterial acquisitions completed in the six months ended 2024-06-30; net assets acquired of $266M including $147M goodwill; headcount added through acquisitions not disclosed
2024-06-30restructuringin_progress2025-12-31GlobalAll segmentsUSD 43 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing actions to align resources and reduce overcapacity; majority of accruals expected to be paid in 2024 and 2025.
2024-06-30restructuringin_progressUSD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progress2025-12-31GlobalUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to align resources, reduce overcapacity, and integrate acquisitions; expected to continue throughout 2024 and into 2025. Severance accrual balance of $34 million as of March 31, 2024; no employee counts disclosed.
2024-03-31restructuringin_progressGlobalConsolidatedUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program to consolidate functions, eliminate redundant positions and reduce overcapacity; $15M expense net of reversals in Q1 2024, severance accrual $34M at quarter-end. Actions expected to continue through 2024 and into 2025; no employee count or announcement date disclosed.
2024-03-31acquisition_additioncompletedTechnology & Analytics Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several individually immaterial acquisitions completed in Q1 2024 ($162M net assets acquired, $103M goodwill, all goodwill recorded in Technology & Analytics Solutions); no headcount added disclosed.
2024-03-31restructuringin_progress2025-12-31GlobalGlobalUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions to align resources and reduce overcapacity; expected to continue into 2025. Majority of accruals expected to be paid in 2024 and 2025.
2024-03-31restructuringin_progressUSD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringin_progressUSD 84 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Full-year 2023 restructuring expense, net of reversals, consisting primarily of severance and other exit-related costs; actions include consolidating functional activities, eliminating redundant positions and aligning resources with customer requirements to reduce overcapacity and integrate acquisitions. Expected to continue into 2024 (no specific completion date disclosed). No employee count affected was disclosed. Severance liability roll-forward: $26M at 2022-12-31, $84M expense net of reversals, $74M paid, $36M balance at 2023-12-31, majority expected to be paid in 2024.
2023-12-31restructuringin_progress2024-12-31GlobalConsolidated; not allocated to reportable segmentsUSD 84 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2023 expense of $84 million, net of reversals, primarily severance and exit-related costs; actions include consolidating functional activities, eliminating redundant positions and aligning resources with customer requirements, and are expected to continue into 2024. No employee count disclosed. Accrual of $36 million outstanding at 2023-12-31, majority expected to be paid in 2024. Reversals during the year reflected redeployment of staff and higher-than-expected voluntary terminations.
2023-12-31acquisition_additioncompletedGlobalTechnology & Analytics Solutions and Research & Development Solutionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Several individually immaterial acquisitions completed during 2023 (net assets acquired $977 million, including $533 million goodwill attributed in part to assembled workforce); no headcount added is quantified. Pro forma results not presented as they would not be materially different.
2023-12-31restructuringin_progress2023-12-312024-12-31GlobalGlobal OperationsUSD 84 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Ongoing efforts to streamline global operations and reduce overcapacity. Actions expected to continue throughout 2024.
2023-12-31restructuringin_progressUSD 84,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30restructuringin_progress2024-12-31USD 67 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2023 restructuring actions to align resources and reduce overcapacity; include consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements. Expected to continue throughout 2023 and into 2024. Severance accrual balance of $42 million as of September 30, 2023; $67 million expense (net of reversals) recorded in the nine months ended September 30, 2023. No employee counts disclosed.
2023-09-30restructuringin_progress2024-12-31GlobalConsolidating functional activities, eliminating redundant positions, aligning resources with customer requirementsUSD 67 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge is nine-month 2023 expense net of reversals; no employee count disclosed. Actions expected to continue through 2023 and into 2024; severance accrual balance $42M at 2023-09-30
2023-09-30restructuringin_progress2024-12-31GlobalGlobalUSD 67 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions to align resources and reduce overcapacity; expected to continue throughout 2023 and into 2024. Majority of accruals expected to be paid in 2023 and 2024.
2023-09-30restructuringin_progressUSD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progress2024-12-31GlobalCompany-wide; costs not allocated to reportable segmentsUSD 20 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2023 actions to align resources, reduce overcapacity, and integrate acquisitions; expected to continue through 2023 and into 2024. Severance liability of $34 million at June 30, 2023; expense net of reversals of $37 million and payments of $29 million in the first six months of 2023. No employee counts disclosed.
2023-06-30restructuringin_progressGlobalNot specified; actions include consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirementsUSD 37 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2023-06-30 expense net of reversals; severance accrual roll-forward: $26M opening, $37M expense, $(29)M payments, $34M closing balance. Filer states actions continue through 2023 and into 2024; no employee count disclosed. Reversals attributed to staff redeployment and higher-than-expected voluntary terminations.
2023-06-30restructuringin_progress2024-12-31GlobalAll segmentsUSD 37 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions to align resources and reduce overcapacity; expected to continue throughout 2023 and into 2024. Includes consolidating functional activities and eliminating redundant positions.
2023-06-30restructuringin_progressUSD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progress2024-12-31GlobalUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to consolidate functions, eliminate redundant positions and align resources; severance accrual rose from $26M to $29M after $17M expense and $14M payments; no employee counts disclosed
2023-03-31restructuringin_progress2024-12-31GlobalNot specified; actions include consolidating functional activities and eliminating redundant positionsUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2023 severance expense net of reversals was $17M; accrual rose from $26M to $29M with $14M paid. Filer does not disclose number of employees affected. Actions described as continuing into 2024 to reduce overcapacity and integrate acquisitions.
2023-03-31restructuringin_progress2024-12-31GlobalAll segmentsUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions include consolidating functional activities, eliminating redundant positions, and aligning resources. Expected to continue into 2024. Reversals due to redeployment and voluntary terminations.
2023-03-31restructuringin_progressUSD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-12-31restructuringin_progress2023-12-31GlobalConsolidated; not allocated to reportable segmentsUSD 28 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2022 expense of $28 million, net of reversals, primarily severance and exit-related costs; actions include consolidating functional activities, eliminating redundant positions and aligning resources with customer requirements. Remaining actions expected to continue into 2023; no employee count disclosed. Accrual balance at 2022-12-31 was $26 million, majority expected to be paid in 2023.
2022-12-31acquisition_additioncompletedGlobalPrimarily Technology & Analytics Solutions and Research & Development Solutionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Several individually immaterial acquisitions completed during 2022; net assets acquired of $1,487 million including $1,026 million goodwill attributed partly to assembled workforce. No headcount added disclosed.
2022-12-31restructuringin_progress2022-01-012023-12-31GlobalAll segmentsUSD 28 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Ongoing efforts to streamline global operations and reduce overcapacity. Remaining actions expected throughout 2023.
2022-12-31restructuringin_progressUSD 28,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-09-30restructuringin_progress2023-12-31USD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2022 restructuring actions to align resources, reduce overcapacity, and integrate acquisitions; $15 million severance expense (net of reversals) recorded in the nine months ended September 30, 2022, with severance accrual of $21 million at quarter-end; actions include consolidating functional activities and eliminating redundant positions; expected to continue into 2023. No employee counts disclosed.
2022-09-30restructuringin_progressGlobalUnallocated — enterprise-wideUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing restructuring to align resources, reduce overcapacity and integrate acquisitions; actions expected to continue into 2023. Severance expense of $15M (net of reversals) for the nine months ended 2022-09-30; accrual balance $21M at period end. No employees-affected count disclosed; reversals reflected redeployment of staff and higher-than-expected voluntary terminations.
2022-09-30restructuringin_progress2023-12-31GlobalGlobalUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing actions to align resources and reduce overcapacity; expected to continue into 2023. Employee count not disclosed.
2022-09-30restructuringin_progressUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progress2023-12-31USD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2022 actions to align resources, reduce overcapacity and integrate acquisitions; include consolidating functions, eliminating redundant positions and aligning resources with customer requirements. Severance expense net of reversals of $11 million in the six months ended June 30, 2022; severance accrual balance of $23 million as of June 30, 2022, with majority expected to be paid in 2022 and 2023. No employee counts disclosed.
2022-06-30restructuringin_progressGlobalConsolidatedUSD 11 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program to consolidate functions, eliminate redundant positions and align resources; $11M expense net of reversals for six months ended 2022-06-30, $23M severance accrual at period end; actions expected to continue into 2023; no employee count disclosed
2022-06-30restructuringin_progress2023-12-31GlobalGlobalUSD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing actions to align resources and reduce overcapacity; expected to continue into 2023. Includes consolidating functional activities and eliminating redundant positions.
2022-06-30restructuringin_progressUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progress2023-12-31GlobalUSD 7 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to align resources, reduce overcapacity, consolidate functions and eliminate redundant positions; expected to continue into 2023. Q1 2022 severance expense of $7 million (net of reversals); severance accrual of $29 million at quarter-end, majority expected to be paid in 2022-2023. No employee counts disclosed.
2022-03-31restructuringin_progressGlobalNot specified — actions described as consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirementsUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance accrual roll-forward: $30M at 2021-12-31, $7M expense net of reversals, $8M payments, $29M at 2022-03-31. No employee count disclosed. Actions expected to continue into 2023; majority of accruals expected to be paid in 2022 and 2023. Reversals attributed to staff redeployment and higher-than-expected voluntary terminations.
2022-03-31acquisition_additioncompletedNot specifiedTechnology & Analytics Solutions and Research & Development Solutions (per goodwill roll-forward)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several individually immaterial acquisitions completed in Q1 2022; net assets acquired $462M, including $339M goodwill and $137M other identifiable intangibles. No headcount added through acquisitions disclosed.
2022-03-31restructuringin_progress2023-12-31GlobalGlobalUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions include consolidating functional activities, eliminating redundant positions, and aligning resources. Expected to continue into 2023.
2022-03-31restructuringin_progressUSD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-12-31restructuringin_progress2022GlobalGlobal operationsUSD 20 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Ongoing management-approved plans to streamline global operations via consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements. FY2021 expense of $20M net of reversals (severance, facility closure and other exit costs); $41M paid in 2021; accrual balance of $30M at year-end with majority expected to be paid in 2022. Remaining actions expected to occur throughout 2022. No employee counts disclosed. Activity reflects current-year column of the multi-year roll-forward only (comparatives of $52M in 2020 and $75M in 2019 not extracted).
2021-12-31acquisition_additioncompletedUSD 1,458 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Several individually immaterial acquisitions completed during FY2021; no acquisition dates or added headcount disclosed. Cash paid for acquisitions, net of cash acquired, was $1,458M per the consolidated statements of cash flows (including $44M of contingent consideration and deferred purchase price); net assets acquired $1,542M, including goodwill of $1,060M and other identifiable intangibles of $576M. Note 8 shows 2021 business-combination goodwill allocated across all three segments (TAS $874M, RDS $160M, CSMS $26M).
2021-12-31restructuringin_progress2022-12-31GlobalGlobal operations — consolidating functional activities, eliminating redundant positions, aligning resources with customer requirementsUSD 20 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2021 expense net of reversals of $20 million (FY2020: $52M, FY2019: $75M); $30 million accrual outstanding at 2021-12-31, majority expected to be paid in 2022; employees affected not disclosed; actions expected to continue into 2022
2021-12-31acquisition_additioncompletedVariousPrimarily Technology & Analytics Solutions and Research & Development Solutionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Several individually immaterial acquisitions completed in 2021 (net assets acquired $1,542 million, goodwill $1,060 million); headcount added through these acquisitions not disclosed
2021-12-31restructuringin_progress2021-01-012022-12-31GlobalVariousUSD 20 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Ongoing efforts to streamline global operations, including consolidating functional activities and eliminating redundant positions. Remaining actions expected to occur throughout 2022.
2021-12-31restructuringin_progressUSD 20,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-09-30restructuringin_progress2022-12-31GlobalUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2021 actions to align resources, reduce overcapacity, consolidate functions and eliminate redundant positions; expected to continue into 2022. Nine-month expense of $15 million (severance and related costs); restructuring accrual balance of $30 million at September 30, 2021, majority expected to be paid in 2021 and 2022. No employee counts disclosed.
2021-09-30restructuringin_progressGlobalConsolidatedUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program: consolidating functions, eliminating redundant positions, aligning resources with customer requirements; expected to continue into 2022. No employee count disclosed. Charge shown is nine-month 2021 severance expense, net of reversals; restructuring accrual balance was $30M at 2021-09-30.
2021-09-30restructuringin_progress2022-12-31GlobalGlobalUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions include consolidating functional activities, eliminating redundant positions, and aligning resources. Expected to continue into 2022. Majority of accruals expected to be paid in 2021 and 2022.
2021-09-30restructuringin_progressUSD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progress2022-12-31GlobalUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to align resources and reduce overcapacity, including consolidating functions and eliminating redundant positions; expected to continue into 2022. Six-month expense, net of reversals, was $13 million (severance and related costs); restructuring accrual of $40 million at June 30, 2021, mostly to be paid in 2021-2022. No employee counts disclosed.
2021-06-30restructuringin_progress2022-12-31GlobalConsolidated (all segments)USD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing 2021 restructuring program: consolidating functional activities, eliminating redundant positions, aligning resources with customer requirements. Charge shown is expense net of reversals for the six months ended June 30, 2021 (severance and related costs $13M; facility exit costs $0M). Q2-only restructuring cost per the income statement was $4M. Restructuring accrual was $40M at June 30, 2021 ($39M severance, $1M facility exit). No employee count, announcement date, or segment/geography split disclosed; actions expected to continue into 2022.
2021-06-30restructuringin_progress2022-12-31GlobalGlobalUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions include consolidating functional activities, eliminating redundant positions, and aligning resources. Expected to continue into 2022. Majority of accruals paid in 2021 and 2022.
2021-06-30restructuringin_progressUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progress2022-12-31GlobalUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to align resources and reduce overcapacity, including consolidating functions and eliminating redundant positions; expected to continue into 2022. Q1 2021 expense of $9 million (severance and related costs); restructuring accrual of $46 million at March 31, 2021. No employee counts disclosed.
2021-03-31acquisition_additionannounced2021-04-01Research & Development Solutions (Q2 Solutions)USD 760 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired the 40% non-controlling interest in Q2 Solutions from Quest Diagnostics for $760 million cash, moving to 100% ownership; no headcount figures disclosed.
2021-03-31restructuringin_progress2022-12-31GlobalNot specifiedUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program: consolidating functions, eliminating redundant positions, aligning resources with customer requirements; actions expected to continue into 2022. Q1 2021 expense was $9M (severance accrual balance $46M at 2021-03-31). No employee count disclosed.
2021-03-31restructuringin_progress2022-12-31GlobalCorporateUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions include consolidating functional activities, eliminating redundant positions, and aligning resources. Expected to continue into 2022.
2021-03-31restructuringin_progressUSD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringin_progress2021-12-31GlobalConsolidating functional activities, eliminating redundant positions, aligning resources with customer requirementsUSD 52 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2020 expense net of reversals; remaining actions expected to continue throughout 2021; employee-affected count not disclosed; accrual balance at 2020-12-31 was $53 million, majority expected to be paid in 2021
2020-12-31acquisition_additioncompletedGlobalMultiple (individually immaterial acquisitions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Several immaterial acquisitions completed in 2020 with total cost of $224 million net of cash acquired; headcount added not disclosed
2020-12-31restructuringin_progress2020-01-012021-12-31GlobalVariousUSD 52 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Ongoing efforts to streamline global operations, including consolidating functional activities and eliminating redundant positions. Remaining actions expected to occur throughout 2021.
2020-12-31restructuringin_progressUSD 52,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-30restructuringin_progress2021-12-31GlobalUSD 50 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2020 actions to align resources and reduce overcapacity; expense net of reversals of $50M (severance and related costs) for nine months ended 2020-09-30; restructuring accrual of $65M at quarter-end, majority expected to be paid in 2020 and 2021. No employee counts disclosed.
2020-09-30restructuringin_progress2021-12-31GlobalAll segmentsUSD 50 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing 2020 restructuring to streamline operations, consolidate functions and eliminate redundant positions; no employee count disclosed. Charge shown is nine-months 2020 expense net of reversals; actions expected to continue into 2021. Severance accrual was $65M at 2020-09-30.
2020-09-30restructuringin_progress2021-12-31GlobalGlobalUSD 50 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing actions to align resources and reduce overcapacity, including consolidating functional activities and eliminating redundant positions. Expected to continue into 2021. No specific employee count disclosed.
2020-09-30restructuringin_progressUSD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progress2021-12-31GlobalUSD 30 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to align resources and reduce overcapacity; expense net of reversals of $30M in H1 2020, primarily severance; accrual balance $57M at June 30, 2020; actions expected to continue into 2021. No employee counts disclosed.
2020-06-30restructuringin_progressGlobalNot specifiedUSD 30 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program to streamline operations: consolidating functions, eliminating redundant positions, aligning resources with customer requirements. $30M expense recorded for six months ended 2020-06-30; severance and facility exit accrual balance $57M at 2020-06-30. Actions expected to continue into 2021; no employee-affected count or announcement date disclosed.
2020-06-30restructuringin_progress2021-12-31GlobalGlobalUSD 30 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions include consolidating functional activities, eliminating redundant positions, and aligning resources. Expected to continue into 2021. Expense net of reversals for six months ended June 30, 2020 was $30 million.
2020-06-30restructuringin_progressUSD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progress2021-12-31GlobalUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to align resources and reduce overcapacity, including consolidating functional activities and eliminating redundant positions; expected to continue into 2021. Q1 2020 expense of $14 million (severance $15M, facility exit credits $(1)M); restructuring accrual balance of $63 million at March 31, 2020, majority expected to be paid in 2020 and 2021. No employee counts disclosed.
2020-03-31restructuringin_progressGlobalNot specified; actions described as enterprise-wide resource alignmentUSD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2020 restructuring expense of $14M (severance and related costs $15M, facility exit costs $(1)M); accrual balance $63M at 2020-03-31. Filer states actions include consolidating functions, eliminating redundant positions and aligning resources, and that they are expected to continue into 2021. No employee count, announcement date, or completion date disclosed.
2020-03-31restructuringin_progress2021-12-31GlobalGlobal OperationsUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions include consolidating functional activities, eliminating redundant positions, and aligning resources. Expected to continue into 2021.
2020-03-31restructuringin_progressUSD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringin_progress2020GlobalUSD 75 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Ongoing multi-year program to align resources, reduce overcapacity, adapt to changing market conditions and integrate acquisitions; actions include closing facilities, consolidating functional activities and eliminating redundant positions. 2019 charge of $75 million is net of reversals; year-end 2019 accrual was $67 million ($64 million severance, $3 million exit costs). First-quarter 2019 included a $9 million decrease in facility exit costs reclassified to a long-term operating lease liability upon ASC 842 adoption. Remaining actions under existing plans, plus upcoming 2020 plans, expected to occur throughout 2020 and consist of severance, facility closure and other exit-related costs. No employee counts affected were disclosed.
2019-12-31restructuringin_progress2020-12-31GlobalNot specifiedUSD 75 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2019 expense of $75M net of reversals for severance, facility closure and exit costs; actions include facility closures, consolidation of functions and elimination of redundant positions. Remaining actions plus 2020 plans expected through 2020. Employees affected not disclosed; $67M accrual balance at 2019-12-31, majority expected to be paid in 2020. Includes a $9M decrease in facility exit costs from ASC 842 reclassification.
2019-12-31acquisition_additioncompletedNot specifiedNot specifiedUSD 667 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Several individually immaterial acquisitions completed in 2019 at $667M total cost net of cash acquired (including $79M contingent consideration and deferred purchase payments); headcount added through these acquisitions is not disclosed.
2019-12-31restructuringin_progress2020-12-31GlobalGlobal operationsUSD 75 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Recognized $75 million of restructuring charges in 2019. Remaining actions expected to occur throughout 2020.
2019-12-31restructuringin_progressUSD 75,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressTwenty Nineteen Restructuring Plan [Member]USD 75,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressTwenty Eighteen Restructuring Plan [Member]USD 68,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressTwenty Seventeen Restructuring Plan [Member]USD 63,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progress2020-12-31GlobalUSD 45 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to align resources and reduce overcapacity, including facility closures, consolidation of functional activities, and elimination of redundant positions; expected to continue into 2020. Restructuring accrual of $53 million at September 30, 2019 ($50 million severance and related costs, $3 million facility exit costs); majority expected to be paid in 2019 and 2020. No employee counts disclosed.
2019-09-30restructuringin_progress2020-12-31GlobalUnallocated (cross-segment)USD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program: facility closures, consolidation, and role eliminations; $45M is nine-month expense net of reversals (Q3 expense $19M); no employee count disclosed; actions expected to continue into 2020
2019-09-30restructuringin_progress2020-12-31GlobalGlobalUSD 45 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing actions to align resources and reduce overcapacity. Expected to continue into 2020. Includes severance and facility exit costs.
2019-09-30restructuringin_progressUSD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progress2020-12-31GlobalUSD 26 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to streamline global operations: closing facilities, consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements; expected to continue into 2020. Restructuring accrual balance of $49 million at June 30, 2019 ($46 million severance and related costs, $3 million facility exit costs); majority expected to be paid in 2019 and 2020. No employee counts disclosed.
2019-06-30restructuringin_progress2020GlobalNot specified; actions include facility closures, functional consolidation and position eliminationsUSD 26 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge is severance expense net of reversals for the six months ended June 30, 2019 (facility exit costs were $0 in the period). No employee count disclosed; restructuring accrual was $49 million at June 30, 2019. Actions expected to continue into 2020. A $9 million facility exit cost decrease in Q1 2019 reflected reclassification to a lease liability under ASC 842.
2019-06-30acquisition_additioncompletedNot specifiedNot specifiedbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several immaterial acquisitions completed in the six months ended June 30, 2019 with total cost of $236 million net of cash acquired (including $35 million contingent consideration and deferred purchase payments); headcount added through these acquisitions was not disclosed.
2019-06-30restructuringin_progress2020-12-31GlobalGlobal OperationsUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing actions to align resources and reduce overcapacity, including closing facilities and eliminating redundant positions. Expected to continue into 2020. YTD expense net of reversals was $26 million.
2019-06-30restructuringin_progressUSD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progress2020-12-31USD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing actions to align resources, reduce overcapacity and integrate acquisitions, including facility closures and elimination of redundant positions; expected to continue into 2020. Restructuring accrual balance of $61 million at March 31, 2019, majority expected to be paid in 2019. No employee counts disclosed.
2019-03-31restructuringin_progress2020-12-31GlobalNot specifiedUSD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2019 expense of $12M net of reversals (severance $12M, facility exit $0); actions include facility closures, functional consolidation and role eliminations, expected to continue into 2020. No employee count disclosed. Accrual balance $61M at 2019-03-31.
2019-03-31acquisition_additioncompletedNot specifiedTechnology & Analytics Solutions; Contract Sales & Medical Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several immaterial acquisitions completed in Q1 2019 with total cost of $210M net of cash acquired (including $35M contingent consideration and deferred purchase payments); no headcount added disclosed.
2019-03-31restructuringin_progress2020-12-31GlobalGlobalUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions include closing facilities, consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements. Expected to continue into 2020.
2019-03-31restructuringin_progressUSD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progress20182019GlobalUSD 68 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Management-approved 2018 plans generated approximately $68 million of restructuring expense in FY2018, net of reversals, comprising severance, facility closure and other exit-related costs under ongoing efforts to streamline global operations; remaining actions (plus 2019 plans) expected throughout 2019. Accrued restructuring liability at year-end was $74 million ($47 million severance, $27 million exit costs). Number of employees affected not disclosed; 2017-plan and 2016-plan activity excluded per current-year-only rule.
2018-12-31restructuringin_progress2019-12-31GlobalNot specified; described as streamlining global operationsUSD 68 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2018 expense net of reversals under 2018-approved plans (severance, facility closure, other exit costs); no employee count disclosed. Remaining actions plus 2019 plans expected to occur throughout 2019; restructuring accrual was $74M at 2018-12-31.
2018-12-31acquisition_additioncompletedNot specifiedPrimarily Technology & Analytics Solutions and Research & Development Solutions (goodwill allocation)USD 372 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total cost of individually immaterial acquisitions completed during 2018, net of cash acquired; headcount added through these acquisitions is not disclosed.
2018-12-31restructuringin_progress2018-01-012019-12-31GlobalAll segmentsUSD 68 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Filer recognized $68 million of restructuring charges in 2018 under existing plans. Remaining actions expected to occur throughout 2019. Employee count not disclosed.
2018-12-31restructuringin_progressUSD 68,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressTwenty Eighteen Restructuring Plan [Member]USD 68,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressTwenty Seventeen Restructuring Plan [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressTwenty Sixteen Restructuring Plan [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progress2019-12-31GlobalUSD 66 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing restructuring actions in 2018 to align resources, reduce overcapacity and integrate acquisitions; include facility closures, consolidation of functional activities and elimination of redundant positions; expected to continue into 2019. Nine-month expense of $66 million (severance $48M, facility exit $18M); restructuring accrual of $85 million at September 30, 2018, majority expected to be paid in 2018 and 2019. No employee counts disclosed.
2018-09-30restructuringin_progressGlobalNot specifiedUSD 66 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing multi-year program (2016-2019) to align resources, reduce overcapacity and integrate acquisitions; actions expected to continue into 2019. Charge is nine-month 2018 expense net of reversals, of which $48M is severance and related costs and $18M facility exit costs. No employee counts disclosed. Accrual balance $85M at 2018-09-30.
2018-09-30acquisition_additioncompletedNot specifiedNot specifiedUSD 286 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several immaterial acquisitions completed during the nine months ended 2018-09-30; total cost $286M net of cash acquired. Headcount added through acquisitions not disclosed.
2018-09-30restructuringin_progress2019-12-31GlobalCorporateUSD 66 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions taken in 2018, 2017, and 2016 to align resources and reduce overcapacity. Expected to continue into 2019. Includes severance and facility exit costs.
2018-09-30restructuringin_progressUSD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progress2019-12-31GlobalNot allocated to reportable segmentsUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing restructuring actions (facility closures, consolidation of functional activities, elimination of redundant positions) to align resources and integrate acquisitions; actions expected to continue into 2019. Restructuring costs are not allocated to segments. No employee counts disclosed.
2018-06-30restructuringin_progress2019-12-31GlobalNot allocated to reportable segmentsUSD 43 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Year-to-date restructuring expense, net of reversals, for the six months ended June 30, 2018; restructuring accrual balance of $81 million at June 30, 2018, with majority expected to be paid in 2018 and 2019. No employee counts disclosed.
2018-06-30restructuringin_progressGlobalNot specified — actions not allocated to reportable segmentsUSD 43 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing restructuring actions in 2018 (closing facilities, consolidating functions, eliminating redundant positions) to align resources and integrate acquisitions; $43M expense for six months ended 2018-06-30 ($17M in Q2). No employee count disclosed; actions expected to continue into 2019; majority of $81M accrual at 2018-06-30 to be paid in 2018 and 2019.
2018-06-30acquisition_additioncompletedNot specifiedNot specifiedUSD 248 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several immaterial acquisitions completed in the six months ended 2018-06-30, total cost net of cash acquired $248M (including $21M contingent consideration/deferred purchase payments); no headcount added disclosed. Charge shown is total acquisition cost, not a workforce charge.
2018-06-30restructuringin_progress2019-12-31GlobalGlobal operationsUSD 43 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions taken in 2018, 2017, and 2016 to align resources and reduce overcapacity. Expected to continue into 2019. Includes severance and facility exit costs.
2018-06-30restructuringin_progressUSD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progress2019-12-31USD 26 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2018 restructuring expense of $26 million comprised $25 million severance and related costs and $1 million facility exit costs; actions include closing facilities, consolidating functions, and eliminating redundant positions, expected to continue into 2019. No employee counts disclosed.
2018-03-31restructuringin_progress2019GlobalUnallocated — across segmentsUSD 26 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2018 charge of $26M ($25M severance, $1M facility exit); actions include facility closures, consolidation and position eliminations, expected to continue into 2019. No employee count disclosed; accrual balance $88M at 2018-03-31.
2018-03-31restructuringin_progress2019-12-31USD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consists of $25M severance and $1M facility exit costs. Actions expected to continue into 2019.
2018-03-31restructuringin_progressUSD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringin_progress20172018USD 63 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2017 net restructuring expense of $63 million (per roll-forward and income statement), of which approximately $61 million arose from 2017 management-approved plans consisting of severance, facility closure and other exit-related costs. Charges are not allocated to reportable segments. Remaining actions under existing plans and upcoming 2018 plans are expected to occur throughout 2018. Affected-employee headcount not disclosed.
2017-12-31restructuringin_progress2018-12-31GlobalCompany-wideUSD 63 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2017 restructuring expense of $63M net of reversals, of which approximately $61M related to 2017 management-approved plans; consisted of severance, facility closure and other exit-related costs. Remaining actions plus 2018 plans expected to occur throughout 2018. Year-end restructuring accrual was $84M; $81M paid during 2017. No employee count disclosed.
2017-12-31divestiture_reductioncompleted2017-07-12United StatesCommercial SolutionsUSD 40 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Encore Health Resources LLC completed 2017-07-12, preceded by $40M of goodwill and intangible impairment charges in FY2017. Headcount removed through the disposition not disclosed.
2017-12-31acquisition_additioncompleted2017-12-31GlobalMultipleUSD 923 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Aggregate cost of individually immaterial acquisitions completed during FY2017, net of cash acquired, was $923M (including $69M contingent consideration and deferred purchase payments). Headcount added through these acquisitions not disclosed.
2017-12-31restructuringin_progress2017-01-012018-12-31GlobalVariousUSD 63 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Recognized $63 million of restructuring charges, net of reversals. Actions expected to occur throughout 2018, consisting of severance, facility closure and other exit-related costs. Employee count not disclosed.
2017-12-31restructuringin_progressUSD 63,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressTwenty Seventeen Restructuring Plan [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressTwenty Sixteen Restructuring Plan [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressTwenty Fifteen Restructuring Plan [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressQuest Diagnostics Incorporated [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-09-30restructuringin_progress2018-12-31USD 35 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month 2017 severance and related costs of $35 million, including ~$6 million related to the IMS Health Merger and ~$29 million for cost-reduction actions to adapt to changing market conditions; actions include closing facilities, consolidating functions, and eliminating redundant positions; expected to continue into 2018. No employee counts disclosed.
2017-09-30divestiture_reductioncompleted2017-07-12Commercial Solutions (Encore Health Resources LLC)USD 40 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of Encore completed July 12, 2017 following $39.6 million goodwill impairment and $0.4 million intangible impairment; no headcount figures disclosed for the divested business.
2017-09-30restructuringin_progress2018-12-31USD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month expense net of reversals: $35M severance (incl. ~$6M Merger-related, $29M cost-reduction) plus $3M exit costs; accrual $79M at 2017-09-30. No employee counts disclosed; actions expected to continue into 2018.
2017-09-30divestiture_reductioncompleted2017-07-12Commercial Solutionsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Encore Health Resources LLC completed 2017-07-12; $40M goodwill and intangible impairment recognized in Q2 2017. Headcount removed not disclosed.
2017-09-30acquisition_additioncompleted2017-09-30USD 579 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Aggregate cost of acquisitions completed in the nine months ended 2017-09-30, net of cash acquired ($390M goodwill, $233M intangibles). Headcount added not disclosed.
2017-09-30restructuringin_progress2018-12-31GlobalCorporateUSD 38 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes severance and related costs of $35 million and exit costs of $3 million. Actions include closing facilities, consolidating functional activities, and eliminating redundant positions. Expected to continue into 2018.
2017-09-30divestiture_reductioncompleted2017-07-12GlobalCommercial Solutionsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of Encore Health Resources LLC completed on July 12, 2017. Associated goodwill impairment of $39.6 million and intangible asset impairment of $0.4 million recognized.
2017-09-30restructuringin_progressUSD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progress2018-12-31USD 28 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six months ended June 30, 2017 restructuring expense, net of reversals, comprising $24 million severance and related costs (including approximately $6 million related to the Merger) and $4 million exit costs. Actions include closing facilities, consolidating functional activities, and eliminating redundant positions; remaining actions expected through 2017 and into 2018. Severance accrual balance of $86 million at June 30, 2017. No employee counts disclosed.
2017-06-30divestiture_reductioncompleted2017-07-12Commercial SolutionsUSD 40 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Company completed the sale of Encore Health Resources LLC to an unrelated third party on July 12, 2017 (subsequent to quarter end). Q2 2017 included a $39.6 million goodwill impairment (remaining Encore goodwill) and $0.4 million intangible asset impairment. Headcount affected not disclosed.
2017-06-30restructuringin_progress2018-12-31GlobalUnallocated (multiple functions)USD 28 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing restructuring program (actions taken 2015-2017) covering facility closures, consolidation and severance; $28M expense net of reversals in six months ended 2017-06-30 (severance $24M, exit costs $4M); accrual balance $90M at 2017-06-30. No employee counts disclosed; actions expected to continue into 2018.
2017-06-30divestiture_reductioncompleted2017-07-12United StatesCommercial Solutions (Encore Health Resources LLC)USD 40 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Encore Health Resources LLC to an unrelated third party completed 2017-07-12 (subsequent event); $40M goodwill and intangible impairment recognized in Q2 2017. Headcount removed through the sale not disclosed.
2017-06-30restructuringin_progress2018-12-31USD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidated restructuring actions including severance and exit costs. Employee count not disclosed. Actions expected to continue into 2018.
2017-06-30restructuringin_progressUSD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progress2018-12-31USD 19 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2017 restructuring expense of $19 million net of reversals: $18 million severance and related costs (approximately $10 million acquisition integration, $8 million cost-reduction actions) and $1 million facility exit costs. No employee counts disclosed. Actions expected to continue into 2018; majority of the $97 million accrual expected to be paid in 2017-2018.
2017-03-31restructuringin_progressUSD 19 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2017 charge of $19M net of reversals: $18M severance (about $10M acquisition integration, $8M cost reduction) plus $1M facility exit costs. No employee count disclosed. Actions began in 2015-2016 (including Merger-related facility consolidation and redundant role eliminations) and are expected to continue into 2018. Restructuring accrual balance $97M at 2017-03-31, majority expected to be paid in 2017 and 2018.
2017-03-31acquisition_additioncompletedCommercial Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Three immaterial acquisitions completed in the Commercial Solutions segment during Q1 2017 for $150M total cost net of cash acquired; no headcount added disclosed. Purchase price allocations preliminary.
2017-03-31restructuringin_progress2018-12-31USD 19 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Actions taken in 2017, 2016, and 2015 are expected to continue into 2018. Includes severance and facility exit costs.
2017-03-31restructuringin_progressUSD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31acquisition_additioncompleted2016-05-032016-10-03GlobalAll segments (primarily Commercial Solutions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger of equals with IMS Health completed 2016-10-03; IMS Health headcount added is not quantified. Merger consideration approximately $10.4 billion; goodwill of $10,288 million recorded. Company-wide headcount disclosed only as 'over 50,000' at year-end.
2016-12-31restructuringin_progress2017-12-31GlobalCompany-wide (includes merger-related facility overcapacity and redundant roles)USD 71 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2016 restructuring charges of $71 million net of reversals per MD&A; footnote roll-forward shows $63 million expense net of reversals plus $80 million of restructuring liabilities acquired with IMS Health. Footnote attributes approximately $33 million to plans approved during 2016, including a merger-related plan to reduce facility overcapacity and eliminate redundant roles. Actions expected to continue throughout 2017; employees affected not disclosed. Year-end accrual $102 million.
2016-12-31divestiture_reductioncompleted2016-06-30South KoreaContract manufacturing joint venture with Samsung Groupother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		During Q2 2016 the Company exercised its right to sell a portion of its JV ownership interest to Samsung for approximately $26 million; associated workforce impact not disclosed. Included for completeness only.
2016-12-31restructuringin_progress2016-01-012017-12-31GlobalVariousUSD 71 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Recognized $71 million of restructuring charges, net of reversals. Actions expected to continue throughout 2017, consisting of severance, facility closure and other exit-related costs. Employee count not disclosed.
2016-12-31restructuringin_progress2016-10-032017-12-31GlobalVariousUSD 87 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Recognized $87 million of merger related costs associated with the IMS Health merger, including severance and termination costs for redundant positions. Employee count not disclosed.
2016-12-31restructuringin_progressTwenty Fourteen Restructuring Plan [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressUSD 71,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressTwenty Sixteen Restructuring Plan [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressQuest Diagnostics Incorporated [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressTwenty Fifteen Restructuring Plan [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-09-30restructuringin_progress2016-01-012017-12-31Company-wideUSD 41 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board-approved 2016 plan of approximately $41 million, primarily severance and other exit costs, to align resources and reduce overcapacity; actions expected to continue throughout 2016 and 2017. Nine-month charges: $22.3M Product Development, $2.2M Integrated Healthcare Services, $2.1M corporate.
2016-09-30restructuringin_progress2015-01-012016-12-31Company-wideUSD 30 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2015 Board-approved plan of approximately $30.0 million to align resources and reduce overcapacity; actions expected to continue throughout 2016. Since inception, approximately $12.0M Product Development, $8.9M Integrated Healthcare Services, $952,000 corporate recognized.
2016-09-30restructuringin_progress2015-07-012017-12-31Product DevelopmentUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in 2015 in connection with the Q2 Solutions joint venture with Quest Diagnostics to reduce facility overcapacity and eliminate redundant roles; approximately $14.0 million of severance, facility closure and other exit costs, with approximately $9.6 million recognized since inception in Product Development.
2016-09-30reduction_in_forcein_progress270Product DevelopmentUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance accrual of $2.4 million at September 30, 2016 relates to cost reduction programs affecting approximately 270 positions; approximately $513,000 of net reversals recognized in first nine months of 2016 in Product Development, primarily from affected individuals transferring to other positions. Majority of accrual expected to be paid in 2017.
2016-09-30restructuringin_progress2017-12-31GlobalCompany-wide (Product Development, Integrated Healthcare Services, corporate)USD 41 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved 2016 plan for severance and exit costs to reduce overcapacity; no employee count disclosed. Costs recognized in 9M 2016: $22.3M Product Development, $2.2M Integrated Healthcare Services, $2.1M corporate. MD&A states restructuring plans together expected to yield annualized savings of $90M-$100M.
2016-09-30restructuringin_progress2016-12-31GlobalCompany-wide (Product Development, Integrated Healthcare Services, corporate)USD 30 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2015 plan approved during 2015; no employee count disclosed. Costs recognized since inception: $12.0M Product Development, $8.9M Integrated Healthcare Services, $0.952M corporate.
2016-09-30restructuringin_progress2017-12-31GlobalProduct DevelopmentUSD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in 2015 in connection with the Quest Diagnostics joint venture to cut facility overcapacity and redundant roles; no employee count disclosed. $9.6M recognized since inception.
2016-09-30restructuringin_progress2702017-12-31GlobalCost reduction programs (primarily Product Development)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance accrual of $2.4M at 2016-09-30 relates to cost reduction programs expected to result in severance for approximately 270 positions; majority expected to be paid in 2017. Net reversals of ~$513,000 recognized in 9M 2016 as affected employees transferred internally.
2016-09-30acquisition_additioncompleted2016-05-032016-10-03GlobalCompany-widesubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger of equals with IMS Health closed 2016-10-03 (subsequent to quarter end); IMS Health results not included in the reported period. No headcount added disclosed; estimated merger consideration ~$10.4 billion with ~126.6 million shares issued. Approximately $82 million of total transaction and integration expenses expected.
2016-09-30restructuringin_progress2016-01-012017-12-31GlobalProduct Development, Integrated Healthcare Services, CorporateUSD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Plan approved for approx $41M. YTD charges of $27.8M recognized. Actions expected to continue throughout 2016 and 2017. Employee count not disclosed.
2016-09-30restructuringin_progress2015-01-012016-12-31GlobalProduct Development, Integrated Healthcare Services, Corporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2015 Plan approved for approx $30M. Actions expected to continue throughout 2016. Employee count not disclosed.
2016-09-30restructuringin_progress2015-01-012017-12-31GlobalProduct Developmentrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Quest Diagnostics joint venture related plan approved for approx $14M. Actions expected to continue throughout 2016 and 2017. Employee count not disclosed.
2016-09-30restructuringin_progress2702017-12-31GlobalProduct DevelopmentUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance accrual related to cost reduction programs resulting in severance for approx 270 positions. Net reversals of $0.5M recognized in YTD 2016 as individuals transferred to other positions.
2016-09-30restructuringin_progressUSD -467,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressTwenty Sixteen Restructuring Plan [Member] / Product Development [Member] / Operating Segments [Member]USD 22,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressTwenty Sixteen Restructuring Plan [Member] / Healthcare Services [Member] / Operating Segments [Member]USD 2,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressTwenty Sixteen Restructuring Plan [Member] / Corporate Non Segment [Member]USD 2,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressTwenty Fifteen Restructuring Plan [Member] / Operating Segments [Member] / Product Development [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressTwenty Fifteen Restructuring Plan [Member] / Operating Segments [Member] / Healthcare Services [Member]USD 8,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressTwenty Fifteen Restructuring Plan [Member] / Corporate Non Segment [Member]USD 952,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressTwenty Fifteen Restructuring Plan [Member] / Operating Segments [Member] / Product Development [Member] / Quest Diagnostics Incorporated [Member]USD 9,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressSeverance And Related Costs [Member]USD 26,470,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressExist Costs [Member]USD 1,321,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progress2016-01-012017-12-31Product DevelopmentUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board approved plan initially for approximately $22 million in Q1 2016, increased to $41 million in Q2 2016, primarily severance and other exit costs to align resources and reduce overcapacity; six-month charge of $21.6 million recognized in Product Development segment.
2016-06-30restructuringin_progress2016-01-012017-12-31Integrated Healthcare ServicesUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six-month charge under the 2016 Plan for Integrated Healthcare Services segment activities.
2016-06-30restructuringin_progress2016-01-012017-12-31CorporateUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six-month charge under the 2016 Plan for corporate activities.
2016-06-30restructuringin_progress2015-01-012016-12-31Product DevelopmentUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2015 plan of approximately $30.0 million to align resources and reduce overcapacity; cumulative-to-date charge of $12.1 million in Product Development segment.
2016-06-30restructuringin_progress2015-01-012016-12-31Integrated Healthcare ServicesUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cumulative-to-date charge under the 2015 plan for Integrated Healthcare Services segment activities.
2016-06-30restructuringin_progress2015-07-012017-12-31Product DevelopmentUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in Q3 2015 in connection with the Quest Diagnostics joint venture transaction to reduce facility overcapacity and eliminate redundant roles; approximately $14.0 million total expected, $11.5 million recognized to date in Product Development.
2016-06-30reduction_in_forcein_progress2702017-12-31Product DevelopmentUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance accrual of $2.7 million at June 30, 2016 relates to cost reduction programs affecting approximately 270 positions; approximately $472,000 of net reversals recognized in the first six months of 2016; majority of accrual expected to be paid in 2017.
2016-06-30restructuringin_progress2017-12-31Consolidated (Product Development, Integrated Healthcare Services, corporate)USD 41 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved the plan in Q1 2016 at about $22 million and raised it to $41 million in Q2 2016 for severance and exit costs; no employee count disclosed. About $25.2 million recognized in H1 2016 ($21.6M Product Development, $1.7M Integrated Healthcare Services, $1.9M corporate). Actions expected to continue through 2016 and 2017; management expects annualized cost savings of roughly $90-100 million.
2016-06-30restructuringin_progress2016-12-31Consolidated (Product Development, Integrated Healthcare Services, corporate)USD 30 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved by the Board in Q1 2015 to align resources and reduce overcapacity; no employee count disclosed. About $21.95 million recognized since inception ($12.1M Product Development, $8.9M Integrated Healthcare Services, $951K corporate); actions expected to continue throughout 2016.
2016-06-30restructuringin_progress2017-12-31Product DevelopmentUSD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approved in Q3 2015 in connection with the Quest Diagnostics joint venture to cut facility overcapacity and redundant roles; no employee count disclosed. About $11.5 million recognized since inception; actions expected to continue through 2016 and 2017.
2016-06-30restructuringin_progress270Product Development (cost reduction programs)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance accrual for cost reduction programs covering approximately 270 positions; accrual was $2.7 million at 2016-06-30 (vs. $3.3 million at 2015-12-31), with net reversals of about $472,000 in H1 2016 as affected employees moved into other roles. Majority of the accrual expected to be paid in 2017; no announcement date or charge amount for the program disclosed.
2016-06-30restructuringin_progress2016-03-312017-12-31GlobalProduct Development, Integrated Healthcare Services, CorporateUSD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Plan approved in Q1 2016 and increased in Q2 2016 to $41 million total. Charges recognized in Q2 2016 include $21.6M (Product Dev), $1.7M (Integrated Healthcare), and $1.9M (Corporate). Actions expected to continue through 2016 and 2017.
2016-06-30restructuringin_progress2015-03-312016-12-31GlobalProduct Development, Integrated Healthcare Services, Corporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2015 Plan approved in Q1 2015 for approx $30.0 million. Actions expected to continue throughout 2016. No specific Q2 2016 charge breakdown provided for this plan in the footnote, but it is part of the ongoing restructuring costs.
2016-06-30restructuringin_progress2015-09-302017-12-31GlobalProduct Developmentrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q3 2015 related to Quest Diagnostics joint venture. Total expected costs approx $14.0 million. Actions expected to continue throughout 2016 and 2017.
2016-06-30restructuringin_progress2702017-12-31GlobalProduct DevelopmentUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance accrual related to cost reduction programs resulting in severance for approx 270 positions. Net reversals of $472,000 recognized in first six months of 2016 primarily due to transfers.
2016-06-30restructuringin_progressUSD 25,114,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progress2016-02-012016-12-31Product DevelopmentUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board-approved plan for approximately $22 million, primarily severance and other exit costs, to align resources and reduce overcapacity; approximately $977,000 recognized in Q1 2016 in the Product Development segment.
2016-03-31restructuringin_progress2015-02-012016-12-31Product Development; Integrated Healthcare Services; corporateUSD 30 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		February 2015 Board-approved plan of approximately $30.0 million to align resources and reduce overcapacity; approximately $12.2 million (Product Development), $8.9 million (Integrated Healthcare Services) and $910,000 (corporate) recognized since inception.
2016-03-31restructuringin_progress2015-07-012017-12-31Product DevelopmentUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in Q3 2015 in connection with the Quest Diagnostics joint venture (Q2 Solutions) to reduce facility overcapacity and eliminate redundant roles; approximately $10.4 million recognized since inception.
2016-03-31reduction_in_forcein_progress2702016-12-31Product DevelopmentUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance accrual of $2.8 million at March 31, 2016 relates to cost reduction programs affecting approximately 270 positions; approximately $537,000 of net reversals recognized in Q1 2016 as affected individuals transferred to other roles.
2016-03-31restructuringin_progress2016-022016-12-31Product DevelopmentUSD 22 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan to align resources and reduce overcapacity; about $977,000 recognized in Q1 2016 for Product Development activities. No employee count disclosed; some actions subject to legal/regulatory requirements.
2016-03-31restructuringin_progress2015-022017-12-31Product Development; Integrated Healthcare Services; corporateUSD 30 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Prior-year plan to reduce overcapacity in certain roles; cumulative charges of $12.2M Product Development, $8.9M Integrated Healthcare Services and $910K corporate since inception. No employee count disclosed.
2016-03-31restructuringin_progress2015-072017-12-31Product DevelopmentUSD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in connection with the Q2 Solutions joint venture with Quest Diagnostics to cut facility overcapacity and redundant roles; about $10.4M recognized since inception. Announcement month inferred from Q3 2015 reference; no employee count disclosed.
2016-03-31restructuringin_progress2702016-12-31Product Developmentother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance accrual of $2.8M at 2016-03-31 relates to cost reduction programs expected to sever about 270 positions; Q1 2016 saw net reversals of about $537K in Product Development as affected staff transferred internally. Majority expected to be paid in 2016. May overlap with the restructuring plans above; accrual is recorded outside the restructuring liability.
2016-03-31restructuringin_progress2016-02-012016-12-31GlobalProduct DevelopmentUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Plan approved in Feb 2016 for approx $22M total. Q1 recognized $977k for Product Development activities. Actions include severance and facility closure.
2016-03-31restructuringin_progress2015-02-012016-12-31GlobalProduct Development, Integrated Healthcare Services, Corporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2015 Plan approved in Feb 2015 for approx $30M total. Actions expected to continue throughout 2016. Includes severance and facility closure.
2016-03-31restructuringin_progress2015-07-012017-12-31GlobalProduct Developmentrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Quest Diagnostics JV related plan approved in Q3 2015 for approx $14M total. Actions expected to continue throughout 2016 and 2017. Includes severance and facility closure.
2016-03-31restructuringin_progress2702016-12-31GlobalProduct DevelopmentUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance accrual related to cost reduction programs resulting in severance for approx 270 positions. Q1 recognized $537k net reversals due to redeployment.
2016-03-31restructuringin_progressUSD 3,144,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31restructuringin_progress2015-022016Product Development; Integrated Healthcare Services; corporateUSD 30 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan of approximately $30.0 million to align resources and reduce overcapacity; 2015 expense of about $11.8M (Product Development), $8.9M (Integrated Healthcare Services) and $0.7M (corporate). No position count disclosed; actions expected to continue through 2016.
2015-12-31restructuringin_progress2015-092017Product DevelopmentUSD 14 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approved in connection with the Quest joint venture to cut facility overcapacity and redundant roles; approximately $8.7 million recognized in 2015. Exact announcement month not disclosed (third quarter 2015); no position count given.
2015-12-31restructuringin_progress270Product Development; Integrated Healthcare ServicesUSD 3 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Separate cost reduction programs expected to result in severance for approximately 270 positions; accrual of $3.3 million at 2015-12-31 (down from $6.3 million at 2014-12-31 due to net reversals). Program predates fiscal 2015; majority of accrual expected paid in 2016.
2015-12-31acquisition_additioncompleted2015-07-012015-07-01GlobalProduct Development (clinical trials laboratories)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Combination of the parties' global clinical trials laboratory operations; Quest received a 40% noncontrolling interest valued at $423.3 million. Headcount added through the transaction is not disclosed.
2015-12-31plant_closurecompleted2015-12-31JapanUSD 3 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Exit of a training facility in Japan, being marketed for sale, resulting in a $2.5 million impairment of land and building. No workforce impact disclosed.
2015-12-31restructuringannounced2016-022016USD 22 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan of approximately $22 million, primarily severance and exit costs, to align resources and reduce overcapacity; some actions subject to legal/regulatory requirements. Expected to reduce service revenues by $18-20 million in 2016 versus 2015. No position count disclosed.
2015-12-31restructuringin_progress2015-022017-12-31GlobalProduct Development, Integrated Healthcare Services, CorporateUSD 12 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		February 2015 plan to align resources and reduce overcapacity. Total expected cost ~$30M. $11.8M recognized in 2015. Actions expected to continue through 2016 and 2017.
2015-12-31restructuringin_progress2015-072017-12-31GlobalProduct DevelopmentUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Q2 Solutions restructuring plan to reduce facility overcapacity and eliminate redundant roles. Total expected cost ~$14M. $8.7M recognized in 2015. Actions expected to continue through 2016 and 2017.
2015-12-31restructuringin_progressUSD 30,752,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringin_progress2015-022016-12-31Product Development; Integrated Healthcare Services; corporateUSD 30 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board-approved plan to align resources and reduce overcapacity in certain roles; consists of severance, facility closure and other exit-related costs. Through September 30, 2015, approximately $11.0 million recognized in Product Development, $3.0 million in Integrated Healthcare Services and $547,000 in corporate activities; all costs to date were severance and related.
2015-09-30restructuringin_progress2015-09-302017-12-31Product DevelopmentUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in Q3 2015 in connection with the Quest joint venture to reduce facility overcapacity and eliminate redundant roles; approximately $8.4 million of restructuring costs recognized in the three and nine months ended September 30, 2015.
2015-09-30reduction_in_forcein_progress2702015-12-31Product Development; Integrated Healthcare ServicesUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance accrual relates to cost reduction programs affecting approximately 270 positions; approximately $944,000 of net reversals recognized in the first nine months of 2015 as affected individuals transferred to other roles. Accrual of $3.6 million at September 30, 2015 vs. $6.3 million at December 31, 2014; majority expected to be paid in 2015.
2015-09-30acquisition_additioncompleted2015-07-012015-07-01Product Development (Q2 Solutions)USD 423 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Clinical trials laboratory joint venture with Quest Diagnostics closed July 1, 2015; Quintiles owns 60% and consolidates with a 40% noncontrolling interest. No employee headcount added was disclosed.
2015-09-30restructuringin_progress2015-022016-12-31Company-wideUSD 30 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan to align resources and reduce overcapacity in certain roles; actions expected throughout 2015 and 2016. Costs recognized to date: ~$11.0M Product Development, ~$3.0M Integrated Healthcare Services, ~$547K corporate. No employee count disclosed.
2015-09-30restructuringin_progress2015-09-302017-12-31Product DevelopmentUSD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in connection with Quest Diagnostics joint venture (Q2 Solutions) to reduce facility overcapacity and eliminate redundant roles; actions expected throughout 2016 and 2017. ~$8.4M recognized in Q3 2015. No employee count disclosed.
2015-09-30restructuringin_progress270Company-wideother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance accrual related to cost reduction programs expected to result in severance for approximately 270 positions. Accrual balance $3.6M at 2015-09-30 (down from $6.3M at 2014-12-31) due to net reversals of ~$944K and payments of ~$1.7M. Announcement date not disclosed; may overlap with the February 2015 restructuring plan.
2015-09-30restructuringin_progress2015-02-012016-12-31GlobalProduct Development, Integrated Healthcare Services, CorporateUSD 30 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		February 2015 plan to align resources and reduce overcapacity. Expected costs of $30.0 million consisting of severance, facility closure and other exit-related costs. Actions expected throughout 2015 and 2016.
2015-09-30restructuringin_progress2015-07-012017-12-31GlobalProduct DevelopmentUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in connection with Q2 Solutions joint venture to reduce facility overcapacity and eliminate redundant roles. Expected costs of $14.0 million. Actions expected throughout 2016 and 2017.
2015-09-30restructuringin_progress2702015-12-31GlobalProduct Development, Integrated Healthcare ServicesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance accrual related to cost reduction programs resulting in severance for approximately 270 positions. Accrual balance of $3.6 million as of Sept 30, 2015. Majority expected to be paid in 2015.
2015-09-30restructuringin_progressUSD 11,984,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progress2015-02-012016-12-31Company-wideUSD 30 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board-approved plan to align resources and reduce overcapacity; actions expected throughout 2015 and 2016, consisting of severance, facility closure and other exit-related costs; expected annualized savings of $50-60 million.
2015-06-30restructuringin_progress2015-02-012016-12-31Product DevelopmentUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cumulative restructuring costs recognized since February 2015 for the Product Development segment; all costs to date relate to severance.
2015-06-30restructuringin_progress2015-02-012016-12-31Integrated Healthcare ServicesUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cumulative restructuring costs recognized since February 2015 for the Integrated Healthcare Services segment; all costs to date relate to severance.
2015-06-30restructuringin_progress2015-02-012016-12-31CorporateUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cumulative restructuring costs recognized since February 2015 for corporate activities; all costs to date relate to severance.
2015-06-30reduction_in_forcein_progress270USD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance accrual of $4.1 million at June 30, 2015 related to cost reduction programs affecting approximately 270 positions; $607,000 of net reversals recognized in H1 2015 as affected individuals transferred to other roles.
2015-06-30restructuringin_progress2015-022016-12-31Product DevelopmentUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan of approximately $30.0 million total to reduce overcapacity in certain roles; actions run through 2015 and 2016. Charge shown is restructuring cost recognized for this segment since February 2015; no employee count disclosed. Expected annualized savings of $50-60 million.
2015-06-30restructuringin_progress2015-022016-12-31Integrated Healthcare ServicesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sub-component of the February 2015 restructuring plan; charge shown is cost recognized for this segment since February 2015. No employee count disclosed.
2015-06-30restructuringin_progress2015-022016-12-31General corporateUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sub-component of the February 2015 restructuring plan; charge shown is cost recognized for corporate activities since February 2015. No employee count disclosed.
2015-06-30restructuringin_progress270Cost reduction programs (Product Development and Integrated Healthcare Services)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separate cost reduction programs expected to result in severance for approximately 270 positions; severance accrual was $4.1 million at June 30, 2015 (down from $6.3 million at December 31, 2014) after net reversals of approximately $607,000 in the first six months of 2015. Announcement date and completion date not disclosed.
2015-06-30acquisition_additioncompleted2015-07-01Clinical trials laboratory operations (Product Development)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		July 1, 2015 closing of joint venture with Quest Diagnostics combining clinical trials laboratory operations (Company 60%, Quest 40%); accounted for as a business combination with a noncontrolling interest. Headcount added not disclosed; purchase price allocation not yet complete.
2015-06-30restructuringin_progress2015-02-012016-12-31GlobalProduct Development, Integrated Healthcare Services, CorporateUSD 30 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Board approved plan in Feb 2015 to align resources and reduce overcapacity. Expected to consist of severance, facility closure and other exit-related costs. No specific employee count disclosed.
2015-06-30restructuringin_progress270GlobalProduct Development, Integrated Healthcare Servicesrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance accrual related to cost reduction programs resulting in severance for approximately 270 positions. Expected to lower operating costs and improve profitability.
2015-06-30restructuringin_progressUSD 6,234,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progress2015-02-012016-12-31Company-wide (Product Development, Integrated Healthcare Services, corporate)USD 30 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board-approved plan of approximately $30.0 million to align resources and reduce overcapacity; actions expected throughout 2015 and 2016, consisting of severance, facility closure and other exit-related costs; expected annualized savings of $50-60 million. Q1 2015 charges recognized: $4.3 million Product Development, $468 thousand Integrated Healthcare Services, $259 thousand corporate; all severance-related. Restructuring accrual balance at March 31, 2015 was $6.9 million.
2015-03-31reduction_in_forcein_progress2702015-12-31Product Development and Integrated Healthcare ServicesUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance accrual of $5.1 million at March 31, 2015 relates to cost reduction programs affecting approximately 270 positions; Q1 2015 net reversals of approximately $443 thousand (about $347 thousand Product Development, $96 thousand Integrated Healthcare Services) as affected individuals transferred to other positions; majority of accrual expected to be paid in 2015.
2015-03-31restructuringin_progress2015-022016Product Development, Integrated Healthcare Services and corporate activitiesUSD 30 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan of approximately $30.0 million to align resources and reduce overcapacity; actions expected throughout 2015 and 2016, consisting of severance, facility closure and exit-related costs. Q1 2015 charge of $5.3 million (all severance), recognized as approximately $4.3 million Product Development, $468 thousand Integrated Healthcare Services and $259 thousand corporate. Company expects annualized cost savings of roughly $50-60 million. No employee count disclosed for the program.
2015-03-31restructuringin_progress270other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separate cost reduction programs expected to result in severance for approximately 270 positions, intended to lower operating costs and improve profitability. Severance accrual balance was $5.1 million at March 31, 2015 (down from $6.3 million at December 31, 2014 after $443 thousand of net reversals, primarily from employees transferring to other positions). Company expects the majority of the accrual to be paid in 2015. Program announcement date not disclosed; accrual existed at December 31, 2014.
2015-03-31restructuringin_progress2015-02-012016-12-31GlobalProduct Development, Integrated Healthcare Services, CorporateUSD 30 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Board approved plan in Feb 2015 to align resources and reduce overcapacity. Expected to consist of severance, facility closure and other exit-related costs. Recognized $5.3M in Q1 2015. Employee count not disclosed.
2015-03-31restructuringin_progress270GlobalProduct Development, Integrated Healthcare ServicesUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance accrual related to cost reduction programs resulting in severance for approximately 270 positions. Accrual balance $5.1M at March 31, 2015.
2015-03-31restructuringin_progressUSD 5,324,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-31restructuringin_progress2502014-12-31Not specifiedConsolidated (plan costs split: Product Development $7.3M, Integrated Healthcare Services $3.0M)USD 13 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan of approximately $13 million to align resources with strategic direction; approximately $10.3 million recognized in 2014 including reversals, all severance and lease costs. Positions not split by segment. Announcement month not disclosed.
2014-12-31restructuringin_progress2702014-12-31Not specifiedOverhead/cost reduction programs (2014 activity: net reversals of approximately $1.7 million)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance accrual of $6.3 million at December 31, 2014 relates to cost reduction programs expected to result in severance for approximately 270 positions; majority expected to be paid in 2015. In 2014 the program recorded net reversals of approximately $1.7 million. May overlap with the 250-position 2014 restructuring plan; filer presents them separately.
2014-12-31acquisition_additioncompleted2014-07-012014-07-01United StatesIntegrated Healthcare Services (EHR implementation and advisory services)USD 92 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed July 1, 2014 for approximately $91.5 million in cash net of acquired cash; acquired headcount not disclosed. Charge value is purchase consideration, not a severance charge.
2014-12-31restructuringannounced2015-02-282016-12-31Not specifiedConsolidatedUSD 30 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board approved in February 2015 a restructuring plan of approximately $30.0 million to align resources and reduce overcapacity; actions expected throughout 2015 and 2016 consisting of severance, facility closure and other exit costs. Employees affected not disclosed; announcement date known only to month.
2014-12-31restructuringcompleted2502014GlobalProduct Development and Integrated Healthcare ServicesUSD 13 (millions)Item 1. Business - Risk Factors
f5-10k / Qwen3.6-27B-Q8_0		Board approved restructuring plans of up to $13 million which resulted in a reduction of approximately 250 positions.
2014-12-31restructuringin_progressUSD 8,988,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressSegment Reconciling Items [Member]USD 8,988,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressOperating Segments [Member] / Twenty Thirteen Restructuring Plan [Member] / Product Development [Member]USD 8,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressOperating Segments [Member] / Twenty Thirteen Restructuring Plan [Member] / Healthcare Services [Member]USD 4,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressOperating Segments [Member] / Twenty Fourteen Restructuring Plan [Member] / Product Development [Member]USD 7,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressOperating Segments [Member] / Twenty Fourteen Restructuring Plan [Member] / Healthcare Services [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressCorporate, Non-Segment [Member] / Twenty Thirteen Restructuring Plan [Member]USD 500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressTwenty Thirteen Restructuring Plan [Member]USD 13,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress250Twenty Fourteen Restructuring Plan [Member]USD 10,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr		Expected positions to be eliminated
2014-09-30restructuringin_progress3502014-02-012014-12-31Product Development and Integrated Healthcare ServicesUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014 Board-approved restructuring plans of approximately $13 million to align resources with strategic direction; all costs are severance; approximately $3.9 million recognized in Product Development and $700,000 in Integrated Healthcare Services through September 30, 2014; expected annualized savings of $20.0-$25.0 million per MD&A
2014-09-30restructuringin_progress2702015-12-31Product Development, Integrated Healthcare Services, and corporateUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cost reduction programs with severance accrual of $7.5 million at September 30, 2014; approximately $2.1 million of net reversals recognized in first nine months of 2014 as affected individuals transferred to other positions; actions expected to occur and be paid during 2014 and 2015
2014-09-30acquisition_additioncompleted2014-07-012014-07-01United StatesIntegrated Healthcare ServicesUSD 92 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Encore Health Resources completed July 1, 2014 for approximately $91.5 million cash net of acquired cash; headcount added not disclosed
2014-09-30restructuringin_progress3502014-022014-12-31Product Development; Integrated Healthcare ServicesUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved 2014 restructuring plans totaling approximately $13 million, all severance-related; actions expected throughout 2014. Through 2014-09-30 roughly $3.9M recognized in Product Development and $0.7M in Integrated Healthcare Services. MD&A states expected annualized cost savings of approximately $20.0 to $25.0 million.
2014-09-30restructuringin_progress2702015-12-31Corporate-wide cost reduction programsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction programs expected to result in severance for approximately 270 positions, with actions expected to occur and be paid during 2014 and 2015. Severance accrual was $7.5 million at 2014-09-30 (down from $14.1 million at 2013-12-31); approximately $2.1 million of net reversals recognized in the first nine months of 2014, primarily as affected individuals transferred internally. Announcement date not disclosed.
2014-09-30restructuringin_progress3502014-02-012014-12-31GlobalProduct Development; Integrated Healthcare ServicesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Board approved plans of approx $13M in Feb 2014. Expected to result in severance for approx 350 positions. Actions expected to occur throughout 2014. Recognized approx $3.9M and $0.7M of costs for Product Development and Integrated Healthcare Services segments respectively through Sept 30, 2014.
2014-09-30restructuringin_progress2702015-12-31GlobalProduct Development; Integrated Healthcare Services; CorporateUSD -2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost reduction programs resulting in severance for approx 270 positions. Expected to occur and be paid during 2014 and 2015. Recognized approx $2.1M of net reversals in first nine months of 2014.
2014-09-30restructuringin_progressUSD 3,749,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressSegment Reconciling Items [Member]USD 3,749,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressTwenty Fourteen Restructuring Plan [Member] / Product Development [Member]USD 3,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressTwenty Fourteen Restructuring Plan [Member] / Healthcare Services [Member]USD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progress350Twenty Fourteen Restructuring Plan [Member]restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2014-06-30restructuringin_progress4002014-02-012014-12-31Product DevelopmentUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board-approved plan of up to $13.0 million to align resources with strategic direction; approximately 400 positions, primarily Product Development; approximately $2.8 million recognized since February 2014, all severance; expected annualized savings of $20.0-$25.0 million
2014-06-30restructuringin_progress2702015-12-31Cost reduction programsUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance accrual of $9.0 million at June 30, 2014 related to cost reduction programs affecting approximately 270 positions; actions expected to occur and be paid during 2014 and 2015; approximately $2.5 million of net reversals recognized in first six months of 2014
2014-06-30acquisition_additionannounced2014-07-012014-07-01United StatesIntegrated Healthcare ServicesUSD 94 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Encore Health Resources completed July 1, 2014 for approximately $93.6 million in cash; no headcount figure disclosed
2014-06-30restructuringin_progress4002014-022014-12-31Product DevelopmentUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan of up to $13.0 million; approximately 400 positions, primarily Product Development. About $2.8 million recognized since February 2014, all severance. MD&A states expected annualized cost savings of $20.0 to $25.0 million.
2014-06-30restructuringin_progress2702015-12-31other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separate cost reduction programs resulting in severance for approximately 270 positions, expected to occur and be paid during 2014 and 2015. Severance accrual was $9.0 million at June 30, 2014; approximately $2.5 million of net reversals recognized in the first six months of 2014. Announcement date not disclosed.
2014-06-30acquisition_additionannounced2014-07-012014-07-01United StatesIntegrated Healthcare ServicesUSD 94 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Encore Health Resources, LLC completed July 1, 2014 for approximately $93.6 million in cash; EHR implementation and advisory services. No headcount added disclosed.
2014-06-30restructuringin_progress4002014-02-012014-12-31GlobalProduct DevelopmentUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Board approved plan in Feb 2014 for up to $13.0M. Expected to result in severance for approx 400 positions, primarily in Product Development. Actions expected to occur throughout 2014.
2014-06-30restructuringin_progress2702015-12-31GlobalVariousrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost reduction programs resulting in severance for approx 270 positions. Expected to occur and be paid during 2014 and 2015.
2014-06-30restructuringin_progressTwenty Fourteen Restructuring Plan [Member] / Product Development [Member]USD 2,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressUSD 1,956,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressMaterial Reconciling Items [Member]USD 1,956,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progress4002014-02-012014-12-31Product Development (primarily)USD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board-approved plan of up to $13.0 million to align resources with strategic direction; approximately 400 positions, primarily Product Development; ~$1.5 million recognized since February 2014, all severance; expected annual cost savings of $20.0-$25.0 million
2014-03-31restructuringin_progress2702015-12-31Cost reduction programs across segmentsUSD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance accrual of $10.9 million at March 31, 2014 for cost reduction programs affecting approximately 270 positions; ~$2.2 million net reversals in Q1 2014 as affected individuals transferred to other positions; actions expected to occur and be paid during 2014 and 2015
2014-03-31restructuringin_progress4002014-022014-12-31Product DevelopmentUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan of up to $13.0M to align resources with strategy; severance for approximately 400 positions, primarily in Product Development, with actions expected throughout 2014. Approximately $1.5M of restructuring costs recognized under this plan since February 2014; income statement restructuring costs for the quarter were $1.008M (includes prior-year plans). Management expects annual cost savings of roughly $20.0–25.0M.
2014-03-31restructuringin_progress2702015-12-31USD 11 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost reduction programs covering approximately 270 positions, expected to occur and be paid during 2014 and 2015, aimed at reducing excess capacity. $10.9M is the severance accrual balance at 2014-03-31 (down from $14.1M at 2013-12-31), not a period charge; a $2.2M net reversal was recognized in Q1 2014, primarily from affected employees transferring into other roles. Announcement date not disclosed.
2014-03-31restructuringin_progress4002014-02-012014-12-31GlobalProduct DevelopmentUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Board approved plan in Feb 2014 for up to $13.0M; expected to result in severance for approx 400 positions, primarily in Product Development. Actions expected to occur throughout 2014.
2014-03-31restructuringin_progress2702015-12-31GlobalProduct Development, Integrated Healthcare Services, Corporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance accrual related to cost reduction programs initiated in prior years. Expected to result in severance for approx 270 positions. Actions expected to occur and be paid during 2014 and 2015.
2014-03-31restructuringin_progressUSD 1,008,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressTwenty Fourteen Restructuring Plan [Member] / Product Development [Member]USD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressMaterial Reconciling Items [Member]USD 1,008,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-31restructuringin_progress4002013-02Product Development and Integrated Healthcare ServicesUSD 14 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan of up to $15.0 million to migrate service delivery (primarily Product Development) and reduce overcapacity (primarily Integrated Healthcare Services); approximately $14.2 million recognized since February 2013, all severance. Positions expected to be reduced as the plan is executed; completion date not stated.
2013-12-31restructuringin_progress2702013-10-012015-12-31Primarily Product Development; also Integrated Healthcare Services and corporateUSD 14 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Separate cost reduction programs recognized in Q4 2013 (exact announcement date not disclosed; date shown is start of quarter); actions expected to occur and be paid during 2014 and 2015. Charge split: $12.3M Product Development, $1.5M Integrated Healthcare Services, $0.3M corporate; $14.1M accrued at year-end, no payments in 2013.
2013-12-31acquisition_additioncompleted2013-09-162013-09-16United States and EuropeProduct Developmentbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired for approximately $146.6 million in cash plus up to $21.0 million contingent earn-out; acquired headcount not disclosed.
2013-12-31restructuringannounced4002014-022014-12-31Primarily Product DevelopmentUSD 13 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board approved in February 2014 a plan of up to $13.0 million to better align resources with strategic direction; actions expected throughout 2014, primarily in Product Development.
2013-12-31restructuringcompleted4002013-02GlobalProduct Development and Integrated Healthcare ServicesUSD 14 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		February 2013 plan to migrate delivery of services and reduce overcapacity. Recognized $14.2 million in costs.
2013-12-31restructuringcompleted2702013-Q42015-12-31GlobalProduct Development, Integrated Healthcare Services, CorporateUSD 14 (millions)other
f5-10k / Qwen3.6-27B-Q8_0		Fourth quarter 2013 cost reduction programs. Expected to be paid during 2014 and 2015.
2013-12-31restructuringin_progressUSD 14,071,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressOperating Segments [Member] / Twenty Thirteen Restructuring Plan [Member] / Product Development [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressOperating Segments [Member] / Twenty Thirteen Restructuring Plan [Member] / Healthcare Services [Member]USD 4,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressTwenty Thirteen Restructuring Plan [Member]USD 14,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressCorporate Non Segment [Member] / Twenty Thirteen Restructuring Plan [Member]USD 469,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressMaterial Reconciling Items [Member]USD 14,071,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress270Cost Reduction Initiative [Member]restructuring_footnote
f5-10k / no-ai-xblr		Expected positions to be eliminated
2013-09-30restructuringin_progress4002013-02-012013-12-31Product Development and Integrated Healthcare ServicesUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		February 2013 Board-approved plan of up to $15.0 million to migrate service delivery (primarily Product Development) and reduce anticipated overcapacity (primarily Integrated Healthcare Services); all costs are severance; expected annualized savings of $15.0-$20.0 million
2013-09-30restructuringin_progress2013-02-012013-12-31Product DevelopmentUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Approximately $9.2 million of severance costs related to the 2013 plan attributable to Product Development segment activities
2013-09-30restructuringin_progress2013-02-012013-12-31Integrated Healthcare ServicesUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Approximately $2.5 million of severance costs related to the 2013 plan attributable to Integrated Healthcare Services segment activities
2013-09-30acquisition_additioncompleted2013-09-162013-09-16United States and EuropeProduct DevelopmentUSD 147 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Novella Clinical Inc. for approximately $146.5 million cash (net of acquired cash) plus earn-out up to $21.0 million; no employee headcount figures disclosed
2013-09-30restructuringin_progress4002013-022013-12-31GlobalPrimarily Product Development (service delivery migration) and Integrated Healthcare Services (overcapacity reduction)USD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan in February 2013 for up to $15.0 million; approximately 400 positions expected to be affected via severance, with actions continuing through 2013. $12.3 million of costs recognized in the nine months ended September 30, 2013 ($7.1 million in the quarter), split approximately $9.2 million Product Development, $2.5 million Integrated Healthcare Services, $0.5 million corporate. Expected annualized savings of $15.0 to $20.0 million.
2013-09-30acquisition_additioncompleted2013-09-16United States and EuropeProduct Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Novella Clinical Inc. completed September 16, 2013 for approximately $146.5 million cash net of acquired cash plus contingent consideration up to $21.0 million. Headcount added through the acquisition is not disclosed; goodwill attributed in part to the assembled workforce.
2013-09-30restructuringin_progress4002013-02-012013-12-31GlobalProduct Development; Integrated Healthcare ServicesUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Board approved plan in Feb 2013 to migrate service delivery and reduce overcapacity. Expected to result in severance for approx 400 positions. Total plan cost up to $15.0 million. YTD charges of $12.3 million recognized.
2013-09-30restructuringin_progressUSD 11,897,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressOperating Segments [Member] / Twenty Thirteen Restructuring Plan [Member] / Product Development [Member]USD 9,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressOperating Segments [Member] / Twenty Thirteen Restructuring Plan [Member] / Healthcare Services [Member]USD 2,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressTwenty Thirteen Restructuring Plan [Member]USD 12,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressCorporate Non Segment [Member] / Twenty Thirteen Restructuring Plan [Member]USD 484,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressMaterial Reconciling Items [Member]USD -11,897,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progress4002013-02-012013-12-31Primarily Product Development; also Integrated Healthcare ServicesUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board-approved plan of up to $15.0 million to migrate service delivery and reduce overcapacity; all costs are severance; expected annual savings of $15.0-$20.0 million. Q2 2013 charge ~$3.2 million ($2.8M Product Development, $1.9M Integrated Healthcare Services, ~$407K corporate); six-month charge ~$5.2 million. Approximately 400 positions affected.
2013-06-30restructuringin_progress4002013-022013-12-31GlobalProduct Development; Integrated Healthcare Services; CorporateUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan of up to $15.0 million to migrate service delivery and reduce overcapacity; approximately 400 positions expected to be affected. Severance recognized in the six months ended June 30, 2013: $5.2 million total, of which $2.8 million Product Development, $1.9 million Integrated Healthcare Services, $0.4 million corporate. Filer states actions continue throughout 2013; expected annual cost savings of $15.0-$20.0 million per MD&A. Announcement date given only as month.
2013-06-30restructuringin_progress4002013-02-012013-12-31GlobalProduct Development; Integrated Healthcare ServicesUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		February 2013 plan to migrate service delivery and reduce overcapacity. Expected to result in severance for approx. 400 positions. YTD charge of $5.2 million.
2013-06-30restructuringin_progressUSD 4,696,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressOperating Segments [Member] / Twenty Thirteen Restructuring Plan [Member] / Product Development [Member]USD 2,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressOperating Segments [Member] / Twenty Thirteen Restructuring Plan [Member] / Healthcare Services [Member]USD 1,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressCorporate Non Segment [Member] / Twenty Thirteen Restructuring Plan [Member] / Corporate Level Activity [Member]USD 407,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressTwenty Thirteen Restructuring Plan [Member]USD 5,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressMaterial Reconciling Items [Member]USD 4,696,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progress4002013-02-012013-12-31Product Development and Integrated Healthcare ServicesUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board approved plan of up to $15.0 million in February 2013 to migrate service delivery and reduce overcapacity; severance for approximately 400 positions; actions expected throughout 2013; expected annual cost savings of $15.0-$20.0 million
2013-03-31restructuringin_progress2013-02-012013-12-31Product DevelopmentUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Approximately $788,000 of Q1 2013 severance costs related to the 2013 plan attributable to Product Development segment activities
2013-03-31restructuringin_progress2013-02-012013-12-31Integrated Healthcare ServicesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Approximately $1.1 million of Q1 2013 severance costs related to the 2013 plan attributable to Integrated Healthcare Services segment activities
2013-03-31restructuringin_progress4002013-022013-12-31Product Development and Integrated Healthcare ServicesUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved February 2013 plan of up to $15.0 million to migrate service delivery (primarily Product Development) and reduce overcapacity (primarily Integrated Healthcare Services); severance for approximately 400 positions, actions expected throughout 2013. Approximately $2.0 million of costs recognized in Q1 2013 (about $788K Product Development, $1.1M Integrated Healthcare Services, $97K corporate), all severance; consolidated restructuring line was $1.9 million net of reversals. MD&A states expected annual cost savings of $15.0 to $20.0 million. Employee count disclosed only on a consolidated basis, not split by segment.
2013-03-31restructuringin_progress4002013-02-012013-12-31GlobalProduct Development; Integrated Healthcare ServicesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Board approved plan in Feb 2013 to migrate service delivery and reduce overcapacity. Expected to result in severance for approx 400 positions throughout 2013. Recognized approx $2.0M costs in Q1 2013.
2013-03-31restructuringin_progressUSD 1,859,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressTwenty Thirteen Restructuring Plan [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressCorporate Level Activity [Member] / Twenty Thirteen Restructuring Plan [Member]USD 97,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressHealthcare Services [Member] / Twenty Thirteen Restructuring Plan [Member]USD 1,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressProduct Development [Member] / Twenty Thirteen Restructuring Plan [Member]USD 788,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr